Lyme disease – treatment assessment based on anti-VIsE antibodies: a pilot study

1. Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 2012;379(9814):461-73.10.1016/S0140-6736(11)60103-7 Search in Google Scholar

2. Hubálek Z. Epidemiology of Lyme borreliosis. Curr Probl Dermatol 2009;37:31-50.10.1159/00021306919367096 Search in Google Scholar

3. Schotthoefer AM, Frost HM. Ecology and epidemiology of Lyme borreliosis. Clin Lab Med 2015;35(4):723-43.10.1016/j.cll.2015.08.00326593254 Search in Google Scholar

4. Eddens T, Kaplan DJ, Anderson AJM, Nowalk AJ, Campfield BT. Insights from the geographic spread of the Lyme disease epidemic. Clin Infect Dis 2019;68(3):426-34.10.1093/cid/ciy510633690729920580 Search in Google Scholar

5. Stanek G, Strle F. Lyme borreliosis – from tick bite to diagnosis and treatment. FEMS Microbiol Rev 2018;42(3):233-58.10.1093/femsre/fux04729893904 Search in Google Scholar

6. Schoen RT. Lyme disease: diagnosis and treatment. Curr Opin Rheumatol 2020;32(3):247-54.10.1097/BOR.000000000000069832141956 Search in Google Scholar

7. Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011;17(1):69-79.10.1111/j.1469-0691.2010.03175.x20132258 Search in Google Scholar

8. Brouqui P, Bacellar F, Baranton G, Birtles RJ, Bjoërsdorff A, Blanco JR, et al. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect 2004;10(12):1108-32.10.1111/j.1469-0691.2004.01019.x15606643 Search in Google Scholar

9. Rauer S, Kastenbauer S, Hofmann H, Fingerle V, Huppertz HI, Hunfeld KP, et al. Guidelines for diagnosis and treatment in neurology – Lyme neuroborreliosis. Ger Med Sci 2020;18:Doc03. Search in Google Scholar

10. O’Connell S. Recommendations for diagnosis and treatment of Lyme borreliosis: guidelines and consensus papers from specialist societies and expert groups in Europe and North America. https://www.cem.scot.nhs.uk/adult/lymeborreliosis.pdf (2.02.2022). Search in Google Scholar

11. Hansmann Y. Treatment and prevention of Lyme disease. Curr Probl Dermatol 2009;37:111-29.10.1159/00021307119367098 Search in Google Scholar

12. Sapi E, Kaur N, Anyanwu S, Luecke DF, Datar A, Patel S, et al. Evaluation of in vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi. Infect Drug Resist 2011;4:97-113. Search in Google Scholar

13. Sharma B, Brown AV, Matluck NE, Hu LT, Lewis K. Borrelia burgdorferi, the causative agent of Lyme disease, forms drug-tolerant persister cells. Antimicrob Agents Chemother 2015;59(8):4616-24.10.1128/AAC.00864-15450524326014929 Search in Google Scholar

14. Lacout A, El Hajjam ME, Marcy PY, Perronne C. The persistent Lyme disease: “True chronic Lyme disease” rather than “Post-treatment Lyme disease syndrome”. J Glob Infect Dis 2018;10(3):170-1.10.4103/jgid.jgid_152_17610033030166820 Search in Google Scholar

15. Rebman AW, Aucott JN. Post-treatment Lyme disease as a model for persistent symptoms in Lyme disease. Front Med 2020;7:57.10.3389/fmed.2020.00057705248732161761 Search in Google Scholar

16. Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001;345(2):85-92.10.1056/NEJM20010712345020211450676 Search in Google Scholar

17. Hunfeld KP, Brade V. Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don’t know, and what we need to know. Wien Klin Wochenschr 2006;118(21-22):659-68.10.1007/s00508-006-0693-z17160604 Search in Google Scholar

18. Wilske B, Fingerle V, Schulte-Spechtel U. Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol Med Microbiol 2007;49(1):13-21.10.1111/j.1574-695X.2006.00139.x17266710 Search in Google Scholar

19. Krzemień PJ. Role of VIsE/C6 antigen as a marker for early Lyme borreliosis diagnosis and monitoring the efectivness of its treatment. Heal Probl Civiliz 2017;11(2):87-92.10.5114/hpc.2017.69023 Search in Google Scholar

20. Wormser GP, Schriefer M, Aguero-Rosenfeld ME, Levin A, Steere AC, Nadelman RB, et al. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 2013;75(1):9-15.10.1016/j.diagmicrobio.2012.09.003405282923062467 Search in Google Scholar

21. Jacek E, Tang KS, Komorowski L, Ajamian M, Probst C, Stevenson B, et al. Epitope-specific evolution of human B cell responses to Borrelia burgdorferi VlsE protein from early to late stages of Lyme disease. J Immunol 2016;196(3):1036-43.10.4049/jimmunol.1501861472249926718339 Search in Google Scholar

22. Marques AR. Laboratory diagnosis of Lyme disease: advances and challenges. Infect Dis Clin North Am 2015;29(2):295-307.10.1016/j.idc.2015.02.005444176125999225 Search in Google Scholar

23. Wojciechowska-Koszko I, Mączyńska I, Szych Z, Giedrys-Kalemba S. Sero-diagnosis of borreliosis: indirect immunofluorescence assay, enzyme-linked immunosorbent assay and immunoblotting. Arch Immunol Ther Exp (Warsz) 2011;59(1):69-77.10.1007/s00005-010-0111-021258869 Search in Google Scholar

24. Lager M, Dessau RB, Wilhelmsson P, Nyman D, Jensen GF, Matussek A, et al. Serological diagnostics of Lyme borreliosis: comparison of assays in twelve clinical laboratories in Northern Europe. Eur J Clin Microbiol Infect Dis 2019;38(10):1933-45.10.1007/s10096-019-03631-x677853431399914 Search in Google Scholar

25. Wojciechowska-Koszko I, Mnichowska-Polanowska M, Kwiatkowski P, Roszkowska P, Sienkiewicz M, Dołęgowska B. Immunoreactivity of Polish Lyme disease patient sera to specific Borrelia antigens – part 1. Diagnostics (Basel) 2021;11(11):2157.10.3390/diagnostics11112157862522234829504 Search in Google Scholar

26. Peltomaa M, McHugh G, Steere AC. Persistence of the antibody response to the VlsE sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of Lyme disease. J Infect Dis 2003;187(8):1178-86.10.1086/37437612695996 Search in Google Scholar

27. Marangoni A, Sambri V, Accardo S, Cavrini F, Mondardini V, Moroni A, et al. A decrease in the immunoglobulin G antibody response against the VlsE protein of Borrelia burgdorferi sensu lato correlates with the resolution of clinical signs in antibiotic-treated patients with early Lyme disease. Clin Vaccine Immunol 2006;13(4):525-9.10.1128/CVI.13.4.525-529.2006145963016603623 Search in Google Scholar

28. Strobino B, Steinhagen K, Meyer W, Scheper T, Saschenbrecker S, Schlumberger W, et al. A community study of Borrelia burgdorferi antibodies among individuals with prior Lyme disease in endemic areas. Health-care (Basel) 2018;6(2):69.10.3390/healthcare6020069602333929921784 Search in Google Scholar

29. Hubálek Z, Halouzka J. Distribution of Borrelia burgdorferi sensu lato genomic groups in Europe, a review. Eur J Epidemiol 1997;13(8):951-7.10.1023/A:1007426304900 Search in Google Scholar

30. Estrada-Peña A, Cutler S, Potkonjak A, Vassier-Tussaut M, Van Bortel W, Zeller H, et al. An updated meta-analysis of the distribution and prevalence of Borrelia burgdorferi s.l. in ticks in Europe. Int J Health Geogr 2018;17(1):41.10.1186/s12942-018-0163-7631979530514310 Search in Google Scholar

31. Philipp MT, Bowers LC, Fawcett PT, Jacobs MB, Liang FT, Marques AR, et al. Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of Borrelia burgdorferi infection in experimental animals and in humans. J Infect Dis 2001;184(7):870-8.10.1086/32339211550127 Search in Google Scholar

32. Philipp MT, Wormser GP, Marques AR, Bittker S, Martin DS, Nowakowski J, et al. A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme borreliosis. Clin Diagn Lab Immunol 2005;12(9):1069-74. Search in Google Scholar

33. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide LM, et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 2008;151(1):42-50.10.1111/j.1365-2249.2007.03545.x227691418005364 Search in Google Scholar

34. John TM, Taege AJ. Appropriate laboratory testing in Lyme disease. Cleve Clin J Med 2019;86(11):751-9.10.3949/ccjm.86a.1902931710588 Search in Google Scholar

35. Kersten A, Poitschek C, Rauch S, Aberer E. Effects of penicillin, ceftriaxone, and doxycycline on morphology of Borrelia burgdorferi. Antimicrob Agents Chemother 1995;39(5):1127-33.10.1128/AAC.39.5.11271626957625800 Search in Google Scholar

36. Brorson Ø, Brorson SH, Scythes J, MacAllister J, Wier A, Margulis L. Destruction of spirochete Borrelia burgdorferi round-body propagules (RBs) by the antibiotic tigecycline. Proc Natl Acad Sci USA 2009;106(44):18656-61.10.1073/pnas.0908236106277403019843691 Search in Google Scholar

37. Feng J, Auwaerter PG, Zhang Y. Drug combinations against Borrelia burgdorferi persisters in vitro: eradication achieved by using daptomycin, cefoperazone and doxycycline. PLoS One 2015;10(3):e0117207.10.1371/journal.pone.0117207437381925806811 Search in Google Scholar